Circurna Appoints Robert Rickert, Ph.D., as Chief Scientific Officer

Veteran immunologist and former Pfizer R&D leader joins Circurna to advance its circular RNA therapeutic platform HOUSTON, TX, UNITED STATES, January 9, 2026 /EINPresswire.com/ — Circurna, a biotechnology company redefining RNA therapeutics through its proprietary circular RNA (ciRNA™) platform, today announced the appointment of Robert Rickert, Ph.D., as Chief Scientific Officer. Dr. Rickert is a […]

uBriGene–Circurna Partnership Accelerates Circular RNA/LNP Therapeutics

uBriGene Biosciences and Circurna Announce Strategic Partnership to Accelerate Development and Manufacturing of Circular RNA/LNP Therapeutics Germantown, MD and Houston, TX (December 09, 2025) — uBriGene Biosciences, a global CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development and manufacturing, today announced a strategic partnership with Circurna, a biotechnology company pioneering next-generation circular RNA (circRNA) […]

What is Circular RNA and Why Does It Matter?

RNA has been at the center of medical innovation in recent years, powering breakthroughs in vaccines and therapeutics. However traditional linear messenger RNA (mRNA) comes with well-known limitations: short-lived protein production, cold-chain storage requirements, and multiple dosing schedules that complicate patient compliance. A new solution is emerging—circular RNA (circRNA). Unlike linear mRNA, circRNA forms a […]